Table 3. Adverse events.
| Total number of adverse events | Number of subjects/%/event count | ||
|---|---|---|---|
| BC1036 (N=141): 76/53.9/158 | Placebo (N=148): 70/47.3/132 | Total (N=289): 146/50.5/290 | |
| Most commonly reported adverse events | |||
| Headache | 18/12.8/25 | 10/6.8/12 | 28/9.7/37 |
| Nasopharyngitis | 8/5.7/8 | 9/6.1/9 | 17/5.9/17 |
| Cough (worsening) | 7/5.0/8 | 9/6.1/9 | 16/5.5/17 |
| Total number of treatment-related adverse events | 32/22.7/65 | 27/18.2/45 | 59/20.4/110 |
| Most commonly reported treatment-related adverse events | |||
| Headache | 15/10.6/20 | 7/4.7/9 | 22/7.6/29 |
| Nausea | 4/2.8/6 | 2/1.4/5 | 6/2.1/11 |
Cell numbers represent the number of subjects, then the percentage of subjects with each event, and then the total number of events.